Look at the comments on past Alnylam (ALNY) articles, and you'll see a vocal cadre of readers who have an otherwise admirable commitment to the notion that Alnylam is going to stumble at some point and not get up … and yet, the company keeps on executing past those worries. While there were some "doom and gloom" comments about how hard COVID-19 would hit the company's lead drug Onpattro, and there certainly has been an impact, the company has been able to manage through that challenge and modestly beat expectations while hitting an all-time high a few weeks ago.
Alnylam will have a lot going over the next 12 or so months, with two expected approvals, and significant clinical data on multiple drugs/indications. I still calculate a near-term fair value of around $150/share, but data updates on vutrisiran, fitusiran, lumasiran, and cemdisiran could all build further value. With that, I still believe this is a good longer-term holding in the biotech space.
Click here to continue:
Alnylam Managing Through Covid-19 Challenges And Executing Well
No comments:
Post a Comment